Ildong Group Ideon, Announces Clinical Efficacy of 'Venadaparib' at American Society of Clinical Oncology

[Financial News] Ideon announced on the 29th that it will present the clinical research results on the combination therapy of the anticancer drug candidate Venadaparib, a PARP inhibitor, at the American Society of Clinical Oncology (ASCO).
Ideon is a new drug development company of the Ildong Pharmaceutical Group, actively engaging in the development and research of anticancer drugs (R&D).
The ASCO annual meeting is the largest event in the field of cancer, attended by oncologists, researchers, and medical and industry professionals worldwide. This year, it will be held in Chicago, USA, from the 30th to June 3rd.
At this conference, Ideon is expected to present the research results obtained from the exploratory analysis of the multinational phase 1b/2a clinical trial (NCT04725994) related to the combination therapy of Venadaparib and Irinotecan for patients with metastatic gastric cancer (mGC) who have undergone third-line or higher treatment, in the form of a poster.
Ideon is developing a new anticancer treatment for metastatic gastric cancer at the third-line or higher treatment stage by combining Venadaparib, a new mechanism PARP inhibitor, with the existing chemotherapy anticancer drug Irinotecan.
According to the company, the median progression-free survival (mPFS) for this indication is only two months, indicating a significant unmet need for new treatment methods.
According to Ideon, a significant correlation between the efficacy of the combination anticancer therapy using Venadaparib for metastatic gastric cancer patients and the homologous recombination deficiency (HRD) gene mutation was confirmed. Particularly, greater potential was shown in patients with HRD gene mutations.
Lee Won-sik, CEO of Ideon, stated, “Being selected as a presentation topic at the world’s most prestigious conference in the field of clinical oncology is expected to further highlight the competitiveness of Venadaparib and the potential for developing new anticancer treatment methods.”

vrdw88@fnnews.com Kang Jung-mo Reporter